+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Medications for Alcohol Use Disorder Market by Product Type (Injectables, Oral Tablets), Drug Class (Acamprosate, Baclofen, Disulfiram) - Global Forecast 2025-2030- Product Image
Medications for Alcohol Use Disorder Market by Product Type (Injectables, Oral Tablets), Drug Class (Acamprosate, Baclofen, Disulfiram) - Global Forecast 2025-2030- Product Image
New

Medications for Alcohol Use Disorder Market by Product Type (Injectables, Oral Tablets), Drug Class (Acamprosate, Baclofen, Disulfiram) - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6128500
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Medications for alcohol use disorder have emerged as a critical pillar in addressing a pervasive public health crisis that affects millions of individuals and families. As the understanding of neurobiological mechanisms deepens, targeted pharmacological interventions have moved to the forefront, offering new hope where behavioral approaches alone have fallen short.

Moreover, the therapeutic landscape has expanded from a narrow array of options to a diverse portfolio of formulations, delivery mechanisms, and adjunctive support tools. This evolution underscores the importance of integrating clinical efficacy with patient-centric considerations such as adherence, tolerability, and quality of life improvements.

Throughout this executive summary, readers will gain a comprehensive overview of the key drivers shaping treatment strategies, transformative shifts redefining patient engagement, and the economic and regulatory factors influencing accessibility. Insight into segmentation dynamics, regional nuances, and leading industry initiatives will provide a solid foundation for strategic decision making in this rapidly advancing field.

Exploring Transformative Shifts Redefining Treatment Paradigms and Patient Engagement Strategies in Alcohol Use Disorder Medications

The landscape of alcohol use disorder medications is undergoing transformative shifts driven by integrated digital health solutions, precision medicine approaches, and evolving patient engagement strategies. Digital therapeutics now complement traditional pharmacological regimens, enabling remote monitoring of medication adherence and offering real-time behavioral support to enhance treatment outcomes.

In addition, precision medicine is gaining traction as genetic and biomarker profiling inform tailored interventions. Pharmacogenomic insights are guiding dose optimization and patient selection, thereby improving efficacy while reducing adverse effects. These advances are reshaping clinical trial designs and accelerating the development of novel compounds.

Furthermore, regulatory frameworks and reimbursement policies are adapting to accommodate innovative therapies. Accelerated approval pathways and value-based contracting models are incentivizing investment in long-acting formulations and combination regimens. Consequently, the industry is poised for a new era in which patient-centered innovation and regulatory agility converge to redefine standards of care.

Assessing the Economic and Regulatory Consequences of United States Tariff Adjustments on Treatment Accessibility and Cost Structures for Patients

Recent adjustments to tariff structures have introduced new layers of complexity into the supply chains that underpin alcohol use disorder therapeutics. Tariffs imposed on active pharmaceutical ingredients and specialty excipients have exerted upward pressure on production costs, compelling manufacturers to reassess sourcing strategies and inventory management practices.

Moreover, these economic pressures have rippled through to distributors and healthcare providers, challenging established pricing models and creating potential barriers to patient access. In response, several producers have pursued strategic stockpiling of critical inputs and diversified supplier networks to cushion the impact of sudden duty increases.

Regulatory agencies and industry associations have engaged in dialogue to mitigate unintended consequences, exploring tariff exemptions for life-saving treatments. Ultimately, this period of adjustment is fostering greater resilience and agility within the pharmaceutical ecosystem, prompting stakeholders to invest in supply chain transparency and collaborative risk-sharing arrangements.

Decoding Critical Segmentation Insights Across Product Types and Drug Classes Informing Strategic Market Positioning in Alcohol Use Disorder Therapeutics

A foundational element in navigating the therapeutic market involves understanding segmentation across product types and drug classes. Based on product type, available interventions span injectables and oral tablets, with injectables encompassing both intramuscular injection and intravenous infusion formats while oral tablets offer extended release and immediate release options. This product-based categorization highlights divergent development pathways and patient adherence considerations.

Equally important is the segmentation by drug class, which includes acamprosate, baclofen, disulfiram, naltrexone, and topiramate. Within this framework, naltrexone commands particular attention through its distinct subcategories: extended release injectable naltrexone and oral naltrexone. These subdivisions not only reflect formulation innovation but also underscore varied administration schedules and adherence profiles.

By decoding these segmentation insights, stakeholders can align research priorities, tailor market entry strategies, and optimize portfolio balance. A nuanced appreciation of both product type and pharmacological class empowers decision makers to anticipate competitive pressures and respond with differentiated offerings that meet evolving patient and provider needs.

Unveiling Region-Specific Dynamics and Growth Drivers Shaping Adoption Trends Across the Americas, Europe Middle East and Africa, and Asia-Pacific Markets

Regional dynamics exert a powerful influence on the adoption and evolution of alcohol use disorder medications. In the Americas, mature healthcare infrastructures and supportive reimbursement landscapes in the United States and Canada have accelerated the uptake of long-acting formulations and combination therapies. Meanwhile, growing awareness campaigns and government initiatives in Latin America are fostering enhanced screening and access programs, setting the stage for broader market penetration.

Across Europe, Middle East & Africa, regulatory harmonization within the European Union has streamlined clinical trial requirements and facilitated cross-border distribution. However, heterogeneous healthcare policies in the Gulf Cooperation Council and North African nations create disparate adoption rates. In sub-Saharan Africa, supply chain challenges and resource limitations underscore the need for cost-effective generics and innovative delivery models.

In Asia-Pacific, rising prevalence rates in countries such as China and India are prompting governments to prioritize public health interventions. Expanded reimbursement frameworks and partnerships with local manufacturers are enabling earlier access to novel therapies. Additionally, increased digital infrastructure is supporting telehealth initiatives, which bridge geographic barriers and enhance patient monitoring.

Highlighting Pioneering Company Initiatives and Collaborative Efforts Accelerating Innovation in Alcohol Use Disorder Medication Development

Industry leaders are intensifying efforts to introduce next-generation therapeutics and formulation technologies that address unmet clinical needs. Major pharmaceutical companies such as Alkermes, Lundbeck, and Indivior have advanced their pipelines through targeted research collaborations and licensing agreements focused on extended release delivery formats.

At the same time, innovative biotechnology firms are pioneering novel mechanism-of-action compounds and exploring combination therapy approaches to enhance relapse prevention. These emerging players are leveraging partnerships with academic centers and contract research organizations to accelerate preclinical validation and streamline regulatory submissions.

Meanwhile, generic manufacturers are optimizing their cost structures and expanding global footprint through strategic alliances. By integrating advanced manufacturing platforms and investing in biosimilar development, they aim to improve affordability and access in both established and emerging markets. Collectively, these initiatives are reshaping competitive dynamics and driving a renewed focus on patient-centric innovation.

Formulating Actionable Strategies and Tactical Recommendations to Enhance Market Competitiveness and Patient Outcomes in Alcohol Use Disorder Therapy

To remain competitive in a dynamically evolving therapeutic environment, industry stakeholders should forge strategic alliances with digital health providers and patient advocacy groups. Such collaborations can yield integrated care models that enhance adherence and deliver real-time support to individuals undergoing treatment.

In addition, investment in advanced formulation research-particularly sustained-release and transdermal systems-can differentiate product offerings and address challenges related to compliance. Harnessing pharmacogenomic insights will further personalize treatments and improve clinical outcomes by aligning therapies with individual patient profiles.

Companies should also cultivate flexible pricing and reimbursement strategies that reflect value-based metrics, ensuring broader access while sustaining commercial viability. This entails negotiating innovative contracts with payers and exploring risk-sharing agreements that link reimbursement to demonstrable patient outcomes.

Finally, maintaining an active dialogue with regulatory bodies will facilitate timely adoption of novel therapeutic modalities. By staying abreast of policy shifts and advocating for expedited review pathways, organizations can accelerate market entry and secure leadership positions in this high-impact segment.

Outlining Rigorous Research Methodologies Employed to Deliver Comprehensive and Credible Insights into Alcohol Use Disorder Treatment Dynamics

The research methodology underpinning this analysis integrates a dual-phase approach to ensure comprehensiveness and credibility. Initial secondary research encompassed a thorough review of peer-reviewed journals, regulatory dossiers, clinical trial registries, and publicly available industry reports to map historical trends and identify key molecular targets.

Subsequently, primary research involved in-depth interviews with leading clinicians, pharmaceutical executives, payer representatives, and patient advocacy leaders. These expert discussions provided nuanced perspectives on real-world treatment challenges, emerging clinical data, and evolving reimbursement environments.

Data were systematically triangulated through qualitative thematic analysis and quantitative cross-validation to mitigate bias and verify findings. Statistical models and scenario planning frameworks were applied to explore potential implications of regulatory changes and supply chain disruptions.

A dedicated validation phase engaged a panel of external experts to review preliminary conclusions and refine insights. This iterative process ensured that the final deliverables reflect robust, evidence-based intelligence aligned with industry best practices.

Concluding Insights that Summarize Key Takeaways and Emphasize Strategic Imperatives for Stakeholders in Alcohol Use Disorder Therapeutics

The insights presented herein illuminate the multifaceted forces shaping the future of alcohol use disorder therapeutics. From the integration of digital health platforms to the implications of tariff adjustments, each factor underscores the importance of adaptive strategies and cross-sector collaboration.

Segmentation analyses reveal targeted opportunities within injectable and oral dosage forms, as well as distinct pharmacological classes, guiding precision in portfolio planning. Regional assessments further highlight divergent growth trajectories across the Americas, Europe Middle East & Africa, and Asia-Pacific, emphasizing the need for tailored market entry approaches.

Innovation led by both established pharmaceutical corporations and agile biotech ventures is expanding treatment possibilities, while generic manufacturers contribute to affordability and access. To capitalize on these developments, stakeholders must embrace patient-centric research, align with payers on value-based models, and maintain proactive engagement with regulatory authorities.

This synthesis of strategic imperatives equips decision makers with the context and direction required to navigate a rapidly evolving therapeutic environment and drive meaningful advances in patient care.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Injectables
      • Intramuscular Injection
      • Intravenous Infusion
    • Oral Tablets
      • Extended Release
      • Immediate Release
  • Drug Class
    • Acamprosate
    • Baclofen
    • Disulfiram
    • Naltrexone
      • Extended Release Injectable Naltrexone
      • Oral Naltrexone
    • Topiramate
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Alkermes plc
  • H. Lundbeck A/S
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Dr. Reddy’s Laboratories Ltd
  • Endo International plc
  • Mallinckrodt plc
  • Pfizer Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increased adoption of off-label gabapentin and topiramate therapies for alcohol use disorder treatment spanning diverse patient populations
5.2. Rising investment in long-acting injectable formulations enhancing medication adherence among patients with alcohol use disorder
5.3. Integration of pharmacogenomic testing to optimize personalized medication regimens for treating alcohol use disorder
5.4. Development of novel dual-acting compounds targeting both craving and withdrawal symptoms in alcohol use disorder patients
5.5. Expansion of digital health platforms supporting remote monitoring and adherence tracking for alcohol use disorder medications
5.6. Strategic partnerships between biotech firms and academic institutions to accelerate clinical trials for innovative AUD therapies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Medications for Alcohol Use Disorder Market, by Product Type
8.1. Introduction
8.2. Injectables
8.2.1. Intramuscular Injection
8.2.2. Intravenous Infusion
8.3. Oral Tablets
8.3.1. Extended Release
8.3.2. Immediate Release
9. Medications for Alcohol Use Disorder Market, by Drug Class
9.1. Introduction
9.2. Acamprosate
9.3. Baclofen
9.4. Disulfiram
9.5. Naltrexone
9.5.1. Extended Release Injectable Naltrexone
9.5.2. Oral Naltrexone
9.6. Topiramate
10. Americas Medications for Alcohol Use Disorder Market
10.1. Introduction
10.2. United States
10.3. Canada
10.4. Mexico
10.5. Brazil
10.6. Argentina
11. Europe, Middle East & Africa Medications for Alcohol Use Disorder Market
11.1. Introduction
11.2. United Kingdom
11.3. Germany
11.4. France
11.5. Russia
11.6. Italy
11.7. Spain
11.8. United Arab Emirates
11.9. Saudi Arabia
11.10. South Africa
11.11. Denmark
11.12. Netherlands
11.13. Qatar
11.14. Finland
11.15. Sweden
11.16. Nigeria
11.17. Egypt
11.18. Turkey
11.19. Israel
11.20. Norway
11.21. Poland
11.22. Switzerland
12. Asia-Pacific Medications for Alcohol Use Disorder Market
12.1. Introduction
12.2. China
12.3. India
12.4. Japan
12.5. Australia
12.6. South Korea
12.7. Indonesia
12.8. Thailand
12.9. Philippines
12.10. Malaysia
12.11. Singapore
12.12. Vietnam
12.13. Taiwan
13. Competitive Landscape
13.1. Market Share Analysis, 2024
13.2. FPNV Positioning Matrix, 2024
13.3. Competitive Analysis
13.3.1. Alkermes plc
13.3.2. H. Lundbeck a/S
13.3.3. Teva Pharmaceutical Industries Ltd
13.3.4. Viatris Inc.
13.3.5. Novartis AG
13.3.6. Sun Pharmaceutical Industries Ltd
13.3.7. Dr. Reddy’s Laboratories Ltd
13.3.8. Endo International plc
13.3.9. Mallinckrodt plc
13.3.10. Pfizer Inc.
14. ResearchAI
15. ResearchStatistics
16. ResearchContacts
17. ResearchArticles
18. Appendix
List of Figures
FIGURE 1. MEDICATIONS FOR ALCOHOL USE DISORDER MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 10. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 12. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 18. MEDICATIONS FOR ALCOHOL USE DISORDER MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 19. MEDICATIONS FOR ALCOHOL USE DISORDER MARKET: RESEARCHAI
FIGURE 20. MEDICATIONS FOR ALCOHOL USE DISORDER MARKET: RESEARCHSTATISTICS
FIGURE 21. MEDICATIONS FOR ALCOHOL USE DISORDER MARKET: RESEARCHCONTACTS
FIGURE 22. MEDICATIONS FOR ALCOHOL USE DISORDER MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY BACLOFEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY BACLOFEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY EXTENDED RELEASE INJECTABLE NALTREXONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY EXTENDED RELEASE INJECTABLE NALTREXONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL NALTREXONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL NALTREXONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY TOPIRAMATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 69. CANADA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 70. CANADA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 71. CANADA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 72. CANADA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 73. CANADA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 74. CANADA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 75. CANADA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 76. CANADA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 77. CANADA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 78. CANADA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 79. MEXICO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 80. MEXICO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 81. MEXICO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 82. MEXICO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 83. MEXICO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 84. MEXICO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 85. MEXICO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 86. MEXICO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 87. MEXICO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 88. MEXICO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 89. BRAZIL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 90. BRAZIL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 93. BRAZIL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 94. BRAZIL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 95. BRAZIL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 96. BRAZIL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 97. BRAZIL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 98. BRAZIL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 99. ARGENTINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 100. ARGENTINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 103. ARGENTINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 104. ARGENTINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 105. ARGENTINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 106. ARGENTINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 107. ARGENTINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 108. ARGENTINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 122. UNITED KINGDOM MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 126. UNITED KINGDOM MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 128. UNITED KINGDOM MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 130. UNITED KINGDOM MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 131. GERMANY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 132. GERMANY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 133. GERMANY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 134. GERMANY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 135. GERMANY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 136. GERMANY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 137. GERMANY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 138. GERMANY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 139. GERMANY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 140. GERMANY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 141. FRANCE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 142. FRANCE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 143. FRANCE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 144. FRANCE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 145. FRANCE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 146. FRANCE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 147. FRANCE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 148. FRANCE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 149. FRANCE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 150. FRANCE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 151. RUSSIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 152. RUSSIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 153. RUSSIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 154. RUSSIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 155. RUSSIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 156. RUSSIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 157. RUSSIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 158. RUSSIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 159. RUSSIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 160. RUSSIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 161. ITALY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 162. ITALY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 163. ITALY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 164. ITALY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 165. ITALY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 166. ITALY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 167. ITALY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 168. ITALY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 169. ITALY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 170. ITALY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 171. SPAIN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 172. SPAIN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 173. SPAIN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 174. SPAIN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 175. SPAIN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 176. SPAIN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 177. SPAIN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 178. SPAIN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 179. SPAIN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 180. SPAIN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 192. SAUDI ARABIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 194. SAUDI ARABIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 196. SAUDI ARABIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 198. SAUDI ARABIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 200. SAUDI ARABIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. SOUTH AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 204. SOUTH AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 206. SOUTH AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 208. SOUTH AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 210. SOUTH AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 211. DENMARK MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 212. DENMARK MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 213. DENMARK MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 214. DENMARK MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 215. DENMARK MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 216. DENMARK MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 217. DENMARK MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 218. DENMARK MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 219. DENMARK MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 220. DENMARK MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 221. NETHERLANDS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 222. NETHERLANDS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 223. NETHERLANDS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 224. NETHERLANDS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 225. NETHERLANDS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 226. NETHERLANDS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 227. NETHERLANDS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 228. NETHERLANDS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 229. NETHERLANDS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 230. NETHERLANDS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 231. QATAR MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 232. QATAR MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 233. QATAR MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 234. QATAR MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 235. QATAR MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 236. QATAR MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 237. QATAR MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 238. QATAR MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 239. QATAR MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 240. QATAR MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 241. FINLAND MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 242. FINLAND MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 243. FINLAND MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 244. FINLAND MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 245. FINLAND MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 246. FINLAND MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 247. FINLAND MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 248. FINLAND MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 249. FINLAND MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 250. FINLAND MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 251. SWEDEN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 252. SWEDEN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 253. SWEDEN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 254. SWEDEN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 255. SWEDEN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 256. SWEDEN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 257. SWEDEN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 258. SWEDEN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 259. SWEDEN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 260. SWEDEN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 261. NIGERIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. NIGERIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. NIGERIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 264. NIGERIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 265. NIGERIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 266. NIGERIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 267. NIGERIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 268. NIGERIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 269. NIGERIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 270. NIGERIA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 271. EGYPT MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 272. EGYPT MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 273. EGYPT MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 274. EGYPT MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 275. EGYPT MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 276. EGYPT MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 277. EGYPT MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 278. EGYPT MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 279. EGYPT MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 280. EGYPT MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 281. TURKEY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 282. TURKEY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 283. TURKEY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 284. TURKEY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 285. TURKEY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2018-2024 (USD MILLION)
TABLE 286. TURKEY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, 2025-2030 (USD MILLION)
TABLE 287. TURKEY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 288. TURKEY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 289. TURKEY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
TABLE 290. TURKEY MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2030 (USD MILLION)
TABLE 291. ISRAEL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 292. ISRAEL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 293. ISRAEL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 294. ISRAEL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 295. ISRAEL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Medications for Alcohol Use Disorder market report include:
  • Alkermes plc
  • H. Lundbeck A/S
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Dr. Reddy’s Laboratories Ltd
  • Endo International plc
  • Mallinckrodt plc
  • Pfizer Inc.

Related Topics

Related Reports

Alcohol Use Disorder Market by Drug Class (Acamprosate, Disulfiram, Naltrexone), Treatment Type (Behavioral Therapy, Combined Therapy, Pharmacotherapy), End User, Distribution Channel, Formulation - Global Forecast 2025-2030 - Product Image

Alcohol Use Disorder Market by Drug Class (Acamprosate, Disulfiram, Naltrexone), Treatment Type (Behavioral Therapy, Combined Therapy, Pharmacotherapy), End User, Distribution Channel, Formulation - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Addiction Disorders Drugs Market by Product Type (Branded, Generic), Dosage Form (Capsule, Film, Injectable Solution), Administration Route, Drug Class, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Addiction Disorders Drugs Market by Product Type (Branded, Generic), Dosage Form (Capsule, Film, Injectable Solution), Administration Route, Drug Class, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Alcohol Use Disorder (AUD) - Market Insight, Epidemiology And Market Forecast - 2032 - Product Image

Alcohol Use Disorder (AUD) - Market Insight, Epidemiology And Market Forecast - 2032

  • Report
  • 152 Pages
  • Global
From
Alcohol Use Disorder Market Report and Forecast 2025-2034 - Product Image

Alcohol Use Disorder Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Addiction Disorders Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Addiction Disorders Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 189 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.